Navigation Links
Evaluate Launches Enhanced Orphan Drug Intelligence
Date:6/17/2013

LONDON and BOSTON, June 17, 2013 /PRNewswire/ --

The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate.  

To better serve its clients' needs in regard to this growing segment of the pharmaceutical industry, Evaluate has enhanced its EvaluatePharma core product database to include in-depth, fact-based orphan drug analysis with data fields for integrated US, EU and Japan orphan drug designations. The enhanced orphan drug content will be available to all EvaluatePharma service clients on June 20, 2013.

"As a company, we are focused on our clients' success. This enhancement allows our clients to size and track the orphan drug market in order to make more informed, strategic decisions about portfolio strategy, growth opportunities and investments," said Anthony Raeside, Head of Research at Evaluate.

EvaluatePharma has identified all products that have orphan drug designations filed in the US, EU or Japan, and has defined a clean 'orphan' sub-set of products through a fully transparent and documented methodology.

The new enhancement facilitates global analysis of the orphan drug R&D and commercial landscape - including the ability to:

  • TRACK the orphan drug market via a transparent methodology
  • MAKE orphan drug commercial assessments
  • CONDUCT competitive intelligence including patent expiries and exclusivities
  • SCREEN for orphan drug licensing opportunities by product, designation, indication
  • BENCHMARK current and historical orphan drug deal terms and values
  • IDENTIFY the future value of an orphan drug market via consensus sales forecasts
  • KNOW the latest news and orphan drug designations and approvals

For more information on the EvaluatePharma service, please visit http://www.evaluategroup.com.  The complimentary Orphan Drug 2013 report is available for download at http://www.evaluategroup.com/orphandrug2013.

If you are attending the 2013 DIA Annual Meeting or the EphMRA 2013 conference and would like to meet, please contact us.

About Evaluate Ltd.

Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape. A team of more than 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award-winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.


Media Contacts:
Evaluate and EP Vantage
Christine Lindgren
+1-617-866-3906
christine.lindgren@evaluategroup.com

Chempetitive Group (for US media)
Rachel Lear
+1-781-775-3640
rlear@chempetitive.com

College Hill (for non-US media)
Melanie Toyne Sewell / Stephanie Bacher / Gemma Howe
+44(0)20-7457-2020
evaluate@collegehill.com


'/>"/>
SOURCE Evaluate Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
2. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
3. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
4. Axela Inc. Retains Investment Bank to Evaluate Strategic Opportunities
5. PathoGenetix and FDA to Evaluate Bacterial Identification System for Use in FDA Public Health and Food Safety Efforts
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
10. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
11. Neogen Launches Fully Quantitative Lateral Flow Test for DON
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):